Widely used:Recently Viewed
Clear All
$82 Mln
--
0.9
--
0
-33.67 %
--
--
--
-421307
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
| -65.84 | 7.84 | 47.55 | -70.11 | -32.58 | -14.45 | -- |
|
BSE Sensex
| 13.00 | 0.56 | 2.05 | 23.70 | 11.01 | 16.81 | 12.01 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
| 73.12 | -42.06 | 38.96 | -44.34 | 71.49 | -75.29 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$81.98 Mln
$0.57 Mln
$0.00 Mln
$76.97 Mln
$16.36 Mln
High
$0.68 - 4.10
70,971,600
NASDAQ: OVID
New York, NY
https://www.ovidrx.com
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a... novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Address: 41 Ninth Avenue, New York, NY, United States, 10001 Read more
The total asset value of Ovid Therapeutics Inc (OVID) stood at $ 132 Mln as on 30-Jun-24
The share price of Ovid Therapeutics Inc (OVID) is $1.10 (NASDAQ) as of 08-Oct-2024 16:00 EDT. Ovid Therapeutics Inc (OVID) has given a return of -32.58% in the last 3 years.
Ovid Therapeutics Inc (OVID) has a market capitalisation of $ 82 Mln as on 08-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Ovid Therapeutics Inc (OVID) is 0.90 times as on 08-Oct-2024, a 71% discount to its peers’ median range of 3.14 times.
Since, TTM earnings of Ovid Therapeutics Inc (OVID) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ovid Therapeutics Inc (OVID) and enter the required number of quantities and click on buy to purchase the shares of Ovid Therapeutics Inc (OVID).
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Address: 41 Ninth Avenue, New York, NY, United States, 10001
The CEO & director of Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir. is Ovid Therapeutics Inc (OVID), and CFO & Sr. VP is Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D..
There is no promoter pledging in Ovid Therapeutics Inc (OVID).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Ovid Therapeutics Inc. (OVID) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.67
|
|
Operating margin(%)
|
-12008.26
|
|
Net Margin(%)
|
-5241.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ovid Therapeutics Inc (OVID) was $0 Mln.
$-0.03
